Cutting edge: Mucosal application of a lyophilized viral vector vaccine confers systemic and protective immunity toward intracellular pathogens

Wolfgang Kastenmuller, Georg Gasteiger, Leon Stross, Dirk H. Busch, Ingo Drexler

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

A major problem of current vaccines is storage stability, often requiring strict maintenance of cold chains. In the course of the eradication of smallpox, a freeze-dried vaccinia virus (Dryvax), which proved to be very stable, was used to overcome this limitation. However, Dryvax needs to be reconstituted before usage and is administered using a bifurcated needle, procedures that pose a number of additional health risks. We report in this study that a stable, lyophilized, modified vaccinia virus Ankara (MVA) vaccine can be directly applied to the nostrils of mice without previous reconstitution. This direct mucosal application induced systemic Ab and T cell responses comparable to those achieved by i.m. administration. Importantly, mucosal application of lyophilized MVA induced long-lasting protective immunity against lethal bacterial and viral challenges. These data clearly demonstrate the potency of a simple needle-free vaccination, combining the advantages of mucosal application with the stability and efficiency of lyophilized MVA.

Original languageEnglish
Pages (from-to)2573-2577
Number of pages5
JournalJournal of Immunology
Volume182
Issue number5
DOIs
StatePublished - 1 Mar 2009
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cutting edge: Mucosal application of a lyophilized viral vector vaccine confers systemic and protective immunity toward intracellular pathogens'. Together they form a unique fingerprint.

Cite this